Trial Profile
Keep persistent efficacy by Abstaining from biological treatment after Numerical SDAI remission with AdalImumab (KANSAI study)
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms KANSAI
- 21 Aug 2013 New trial record